Shen Lian Biomedical: The company's production and operations are normal, with no undisclosed significant matters that need to be disclosed

Shen Lian Biomedical Co., Ltd. announced that its stock price deviation exceeded 30% over three consecutive trading days from August 14 to 15, 2025, indicating abnormal fluctuations. After self-examination, the company confirmed that its production and operations are normal, and there are no undisclosed significant matters that should be disclosed. The company has noted the high market attention on its innovative drug business and is increasing its investment in the human innovative drug field through its subsidiary to the joint venture company Shizhi Yuan. Currently, the three innovative drug pipelines are at different stages of research and development, with uncertainties regarding clinical results and market launch. The company warns of the risks associated with innovative drug research and development as well as secondary market trading risks, reminding investors to invest rationally